📊 Key Data Readouts Left for the Quarter: Weekly Watchlist 📊
This week, we’re spotlighting the biotech companies with critical catalysts & data readouts left in Q3 2024. Here’s what to keep an eye on:
Enanta Pharmaceuticals (NASDAQ: ENTA) is gearing up for a significant moment with the expected release of topline data from its Phase 2a study of Zelicapavir (EDP-323), an oral antiviral for RSV, by the end of Q3 2024. Positive results could strengthen Enanta’s position in the RSV market, supporting further clinical development and enhancing its overall pipeline value.
Zevra Therapeutics (NASDAQ: ZVRA) is on the cusp of a potential breakthrough with the PDUFA date for Arimoclomol, a treatment for Niemann-Pick disease Type C, set for September 21, 2024. Following a favorable Advisory Committee vote, there’s renewed optimism for FDA approval. Success here would make Arimoclomol the first approved treatment for NPC in the U.S., potentially transforming Zevra’s market standing.
Heron Therapeutics (NASDAQ: HRTX) is awaiting an FDA decision on a Post-Approval Supplement (PAS) for ZYNRELEF, expected by September 23, 2024. A positive outcome could expand ZYNRELEF's label, increasing its market potential in postoperative pain management and enhancing Heron’s growth trajectory.
Vanda Pharmaceuticals (NASDAQ: VNDA) has a pivotal moment coming up with the PDUFA date for Tradipitant, a potential new treatment for gastroparesis, on September 18, 2024. Approval could provide a significant new revenue stream and diversify Vanda’s portfolio beyond its current CNS-focused offerings.
Stay tuned next week as we continue to cover catalysts remaining for Q3 before we refresh our watchlist for the end of the year. Which of these catalysts are you most excited about? Share your thoughts! 🔍
#Biotech #Pharma #DrugDevelopment #FDA #ClinicalTrials #Investing #HealthcareInnovation #BiotechStocks #BeThereWhenItHappens #FasterScience #BiotechInvesting